In a double-blind clinical trial on 49 patients with rheumatoid arthritis, calciferol was given in a dose of 100 000 IU per day for 1 year to 24 patients, while the remaining 25 received placebo. Objective and subjective improvement was noted in 67% of the calciferol group and in 36% of the control group, while objective and subjective deterioration was noted in 4% of the calciferol group and in 32% of the control group. The mean values for sedimentation rate and a2-globulin decreased and the mean hemoglobin level increased in the calciferol group. The consumption of analgesics and antiinflammatory medicines decreased significantly in the calciferol group and after 1 year morning stiffness had eased and hand strength had increased in this group.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.